- First preclinical data for newly-announced IL4I1 immuno-oncology program
- Preclinical data for orally bioavailable CD73 inhibitor CB-708
“The preclinical IL4I1 immuno-oncology program is an exciting new addition to our pipeline, and we are pleased that initial data from this program, as well as our ongoing CB-708 preclinical program, have been accepted for presentation at this high-profile meeting,” said
Details of the poster presentations are as follows:
|Title:||Anti-tumor activity of a small molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)|
|Date:||Friday, November 8, 2019 at 7:00 am-8:00 pm ET|
|Title:||CB-708, an orally bioavailable small molecule inhibitor of CD73 with immunostimulatory and anti-tumor activity|
|Date:||Saturday, November 9, 2019 at 7:00 am-8:30 pm ET|
IL4I1 is an enzyme that is primarily expressed by tumor cells and antigen presenting cells, and produces hydrogen peroxide, an inhibitor of T-cell function. IL4I1 has a potential role in immune evasion and decreases the ability of checkpoint therapy to mount an anti-tumor immune response. Calithera’s pipeline includes an investigational first-in-class, potent, orally available IL4I1 inhibitor.
CB-708 is a small molecule inhibitor of CD73, which is an enzyme in the tumor microenvironment that produces adenosine, a powerful inhibitor of immune function in tumors. CD73 is expressed across a wide range of tumor types and tumor infiltrating leukocytes. Expression of CD73 often correlates with poor prognosis in patients with cancer. Blockade of adenosine production by CD73 inhibition is expected to reverse immunosuppression in the tumor microenvironment and enhance the immune system’s ability to fight the cancer. CB-708 is orally bioavailable and shows distribution to all tissues, including the brain.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the
SOURCE: Calithera Biosciences, Incorporated
Source: Calithera Biosciences, Inc.